- Clinical Trials
- January 2024
- 100 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- May 2023
- 220 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2023
- 450 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- September 2022
- 239 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- August 2022
- 151 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Clinical Trials
- August 2022
- 150 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- April 2020
- 80 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- July 2023
- 140 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- September 2024
- 82 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- January 2024
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- October 2023
- 145 Pages
Global
From €3006EUR$3,150USD£2,519GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- February 2024
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Europe
From €4533EUR$4,750USD£3,798GBP

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body.
PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more